Meeting
2021 ASCO Annual Meeting
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
Authors
Jia Ruan
Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
Jia Ruan , Jasmine M. Zain , Brett Palmer , Borko Jovanovic , Xinlei Mi , Alok Swaroop , Jane Winter , Leo I. Gordon , Reem Karmali , Barbara Pro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02232516
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7514)
DOI
10.1200/JCO.2021.39.15_suppl.7514
Abstract #
7514
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.
First Author: G. S. Nowakowski
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2021 ASCO Annual Meeting
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
First Author: Michael B. Atkins
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.
First Author: Taymeyah E. Al-Toubah